Farxiga® and Warfarin

Publication Date: 
Mon, 06/01/2015
By: Alere Staff

There are a total of 29.1 million people, or 9.3 percent of the population in the United States, that are diagnosed with diabetes. Of these people, 1.7 million have Type 2 Diabetes, where the body produces insulin but cannot use the insulin produced properly. Type 2 Diabetes can be prevented or delayed by losing weight, eating healthy and being more active. When these measures fail, then disease management can be helped with the addition of medications to already existing measures.1

One of the newest medications recently approved in 2014 by the U.S Food and Drug Administration (FDA) is Farxiga®, generic name Dapagliflozin. This oral medication is classified as a SGLT2 inhibitor which works by blocking the reabsorption of sugar in the kidneys. The excess sugar is then released in urine, thereby decreasing the patient’s blood sugar. According to the manufacturer’s package insert, there is currently no reported interaction with warfarin. The drug may be used alone or in conjunction with other diabetic drugs. The goal is to decrease blood sugar with medication, diet and exercise.2

Patients are always advised to discuss any changes or additions to their medication regimen with the provider who manages their warfarin therapy. The discussion should also include any changes that may be made to their diet or lifestyle to manage diabetes.  Both of these changes may require patients to have additional blood tests to monitor warfarin usage to keep the patient in the appropriate therapeutic range.


  1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014. Retrieved from website: www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html
  2. Farxiga® package insert. AstraZeneca pharmaceuticals, March 2015.

Farxiga® is a registered trademark of the AstraZeneca group of companies.